GLP-1 Receptor Agonist Global Market Opportunities And Strategies To 2035

GLP-1 Receptor Agonist Market Definition

GLP-1 receptor agonist are a class of medications that mimic the action of the natural hormone glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels. These drugs enhance insulin secretion, reduce glucagon production, slow gastric emptying and promote satiety. The primary purpose of GLP-1 receptor agonist is to improve blood glucose control and support weight reduction in patients with type 2 diabetes or obesity. The GLP-1 receptor agonist market consists of sales, by entities (organizations, sole traders, or partnerships), of products and services related to GLP-1 receptor agonist, that gained approval for use in individuals with obesity, including those without diabetes, to assist in achieving and maintaining weight loss, especially in cases where traditional lifestyle interventions have been ineffective.

GLP-1 Receptor Agonist Market Segmentation

The GLP-1 receptor agonist market is segmented by drug class, by route of administration and by end-user industry.

By Type –
The GLP-1 receptor agonist market is segmented by drug class into:

• a) Liraglutide
• b) Semaglutide
• c) Tirzepatide
• d) Dulaglutide
• e) Other Drugs

The semaglutide market was the largest segment of the GLP-1 receptor agonist market segmented by drug class, accounting for 51.9% or $34,188.0 million of the total in 2025. Going forward, the tirzepatide segment is expected to be the fastest growing segment in the GLP-1 receptor agonist market segmented by drug class, at a CAGR of 17.8% during 2025-2030.

By Route Of Administration –
The GLP-1 receptor agonist market is segmented by route of administration into:

• a) Parenteral
• b) Oral

The parenteral market was the largest segment of the GLP-1 receptor agonist market segmented by route of administration, accounting for 81.2% or $53,493.9 million of the total in 2025. Going forward, the oral segment is expected to be the fastest growing segment in the GLP-1 receptor agonist market segmented by route of administration, at a CAGR of 25.3% during 2025-2030.

By End-User –
The GLP-1 receptor agonist market is segmented by end-user into:

1. a) Hospitals
2. b) Surgical Clinics
3. c) Other End-Users

The hospitals market was the largest segment of the GLP-1 receptor agonist market segmented by end users, accounting for 55.1% or $36,266.2 million of the total in 2025. Going forward, the hospitals segment is expected to be the fastest growing segment in the GLP-1 receptor agonist market segmented by end users, at a CAGR of 17.1% during 2025-2030.

By Geography - The GLP-1 receptor agonist market is segmented by geography into:

o Asia Pacific
• • China
• • India
• • Japan
• • Australia
• • Indonesia
• • South Korea
o North America
• • USA
• • Canada
o South America
• • Brazil
o Western Europe
• • France
• • Germany
• • UK
• • Italy
• • Spain
o Eastern Europe
• • Russia
o Middle East
o Africa

North America was the largest region in the GLP-1 receptor agonist market, accounting for 72.63% or $47,836.01 million of the total in 2025. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the GLP-1 receptor agonist market will be Africa and Middle East where growth will be at CAGRs of 33.25% and 29.92% respectively. These will be followed by Eastern Europe and South America where the markets are expected to grow at CAGRs of 26.44% and 26.42% respectively.

GLP-1 Receptor Agonist Market Drivers

The key drivers of the GLP-1 receptor agonist market include: Rise In Obesity Rates During the forecast period, the rise in obesity rates will propel the growth of the GLP-1 receptor agonist market. Increasing global obesity prevalence heightens the need for effective pharmacological interventions that can address weight gain, metabolic dysfunction and the progression of obesity-related chronic diseases. Obesity significantly elevates the risk of conditions such as type 2 diabetes, hypertension and cardiovascular disorders, creating stronger demand for treatments capable of producing sustained weight loss and improving overall metabolic health. This sharp increase in obesity rates expands the population requiring structured weight-management therapies and clinical support. As more individuals face health risks associated with excess weight, the demand for GLP-1 receptor agonist, proven to reduce weight, improve glycemic control and lower cardiometabolic risk, is expected to rise substantially, thereby driving the growth of the GLP-1 receptor agonist market. The rise in obesity rates growth contribution during the forecast period in 2025 is 4.5%.

GLP-1 Receptor Agonist Market Restraints

The key restraints on the GLP-1 receptor agonist market include: High Drug Costs Compared To Standard Diabetes Or Obesity Therapy High drug costs compared to standard diabetes or obesity therapy are restricting the growth of the GLP-1 receptor agonist market during the forecast period. GLP-1 drugs remain significantly more expensive than traditional treatments, creating financial barriers for patients and limiting adoption among those without comprehensive insurance coverage. Their high monthly price also places pressure on payers, who may impose restrictions, prior authorizations, or step-therapy requirements that reduce access. Additionally, cost-effectiveness analyses have shown that current GLP-1 pricing does not align with accepted value thresholds, making health systems less likely to support broad reimbursement. As a result, many individuals and providers continue to rely on lower-cost diabetes or weight-management therapies, limiting the potential expansion of GLP-1 receptor agonist. Growth affected by high drug costs compared to standard diabetes or obesity therapy across regions during the forecast period in 2025 is -0.8%.

GLP-1 Receptor Agonist Market Competitive Landscape

Major Competitors are:

Novo Nordisk AS

Eli Lilly Company

AstraZeneca Inc.

Sanofi SA

Glenmark Pharmaceuticals Limited

Other Competitors Include:

Teva Pharmaceutical Industries Ltd.

Amneal Pharmaceuticals

Johnson & Johnson

Daiichi Sankyo Company Limited

Mitsubishi Tanabe Pharma Corporation

Merck & Co., Inc.

Boehringer Ingelheim International

Hanmi Pharmaceutical Co., Ltd

Amgen

PegBio Co., Ltd

Bristol-Myers Squibb Company

Chongqing Lummy Pharmaceutical Co. Ltd

Dong-A ST Co. Ltd.

YaoPharma Co., Ltd.

Innovent Biologics, Inc.

Hansoh Pharma

Sciwind Biosciences

Hangzhou Jiuyuan Gene Engineering Co., Ltd

Daewoong Pharmaceutical Co., Ltd.

Celltrion Pharm, Inc.

Yuhan Corporation

Chong Kun Dang pharmaceutical Corp

Nxera Pharma

Corden Pharma GmbH

Merck Sharp & Dohme

Zealand Pharma A/S

Ascendis Pharma

Geropharm

Sun Pharmaceutical Industries Ltd.

Jiangsu Hengrui Medicine Co.

Novartis AG

GLP-1 Receptor Agonist Market Trends

Major trends shaping the GLP-1 receptor agonist market include: Development Of Oral GLP-1 Candidates To Expand Patient Convenience And Treatment Accessibility Major companies in the GLP-1 receptor agonist market are focusing on the development of oral GLP-1 formulations designed to address rising global demand for more convenient, non-injectable metabolic therapies. These innovations aim to improve treatment adherence, reduce reliance on injectable delivery systems and broaden therapeutic accessibility for individuals managing obesity and type 2 diabetes. For instance, in April 2025, Pfizer, a US-based pharmaceutical company specializing in metabolic and cardiometabolic drug development, provided an update on its oral GLP-1 receptor agonist candidate, danuglipron, following the completion of once-daily formulation studies intended to improve dosing convenience for patients. While the candidate achieved pharmacokinetic objectives, the program was discontinued due to a single case of potential liver injury among over 1,400 trial participants. This update underscores both the promise and the complexity of advancing oral GLP-1 drug technology, highlighting ongoing industry efforts to balance innovation, safety and patient-centric design as companies work to meet evolving global treatment needs. Integration Of Dual GLP-1/GIP Agonist To Enhance Weight-Loss Efficacy In Obesity Treatment Major companies in the GLP-1 receptor agonist market are focusing on the integration of dual GLP-1/GIP agonist therapies designed to deliver greater weight-loss efficacy and broader metabolic benefits compared to traditional single-pathway treatments. These innovations aim to offer more potent and durable clinical outcomes, improve patient responsiveness and address the growing need for advanced therapies within the global obesity landscape. For instance, in August 2025, Viking Therapeutics, a US-based company specializing in metabolic and endocrine disorder treatments, announced positive top-line results from its Phase 2 VENTURE-Oral Dosing trial of VK2735, an investigational oral dual GLP-1/GIP agonist for obesity. The 13-week study met primary and key secondary endpoints, showing dose-dependent weight loss with once-daily dosing. Higher doses (90 mg and 120 mg) achieved up to 12.2% mean reduction from baseline (26.6 lbs) versus 1.3% (2.9 lbs) for placebo, with up to 97% of patients losing ≥5% of body weight. VK2735 was well tolerated, with mostly mild/moderate adverse events and low discontinuations. These results, building on prior subcutaneous data, highlight its potential as a promising oral obesity therapy.

Opportunities And Recommendations In The GLP-1 Receptor Agonist Market

Opportunities – The top opportunities in the GLP-1 receptor agonist markets segmented by drug class will arise in the semaglutide segment, which will gain $38,237.9 million of global annual sales by 2030. The top opportunities in the GLP-1 receptor agonist markets segmented by route of administration will arise in the parenteral segment, which will gain $47,566.5 million of global annual sales by 2030. The top opportunities in the GLP-1 receptor agonist markets segmented by end users will arise in the hospitals segment, which will gain $43,597.5 million of global annual sales by 2030. The GLP-1 receptor agonist market size will gain the most in the USA at $36,441.0 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the GLP-1 receptor agonist companies to focus on expanding oral and patient-centric GLP-1 therapies, focus on advancing dual GLP-1/GIP therapies for superior obesity outcomes, focus on developing dual GLP-1/glucagon agonists for metabolic liver disease, focus on expanding semaglutide and tirzepatide offerings to capture high-growth segments, focus on expanding oral glp-1 therapies to capture rapidly growing market demand, focus on wind power systems as the fastest-growing segment, focus on variable speed drives to capture high-growth opportunities, focus on expanding distribution channels across non-traditional care settings, focus on strategic pricing to enhance market access and competitiveness, focus on educating healthcare providers to drive adoption, focus on patient-centric awareness campaigns to expand engagement, focus on expanding GLP-1 access through other users channels.